ASPCF News and Press, Acerus Pharmaceuticals Corp From 02/05/20

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of two NATESTO ® clinical studies for presentation at the American Urological Association’s AUA2020 Scientific Program. The AUA2020 mee...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of a scientific abstract reporting the results of the NATESTO ® Spermatogenesis Study by the Endocrine Society for presentation at their Annua...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that the dossier filed as a Decentralized Procedure in 19 European countries for the approval of NATESTO ® has been withdrawn. The regulatory dossier was fil...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it has closed the previously announced amendment and restatement of the US$5.0 million subordinated secured term loan facility previously entered into on July...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amendment agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter...

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB: ASPCF) announced today that Edward Gudaitis, President and Chief Executive Officer, will present an overview of the company at the 12 th Annual LD Micro Main Event investor conference at 3:40 pm Pacific Time on Tuesday December 10, 2019 at ...

Closing conditions waived - Amended & Restated Partnership Agreement is now closed Acerus-Aytu jointly led commercial effort behind NATESTO ® in the United States is now initiated Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the rev...

Acerus Pharmaceuticals Corporation (ASPCF) Q3 2019 Earnings Conference Call November 14, 2019 8:30 AM ET Company Participants Bob Motz – Chief Financial Officer Ed Gudaitis – President and Chief Executive Officer Conference Call Participants Presentation Op...

Acerus Pharmaceuticals ( OTCQB:ASPCF ): Q3 GAAP EPS of -$0.02. More news on: Acerus Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three- and nine-month period ended September 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accor...